gms | German Medical Science

25th Annual Meeting of the German Retina Society

German Retina Society

01.06. - 02.06.2012, Münster

Cat scratch disease – an important retinal and neuroopthalmologic differential diagnosis

Meeting Abstract

  • Andreas Lipski - Augenklinik der Charité CVK Berlin
  • J. Buer - Institut für Medizinische Mikrobiologie der Universität Essen
  • A.M. Joussen - Augenklinik der Charité CVK Berlin
  • N. Bornfeld - Universitäts-Augenklinik Essen
  • C. Metz - Universitäts-Augenklinik Essen

German Retina Society. 25th Annual Conference of the German Retina Society. Münster, 01.-02.06.2012. Düsseldorf: German Medical Science GMS Publishing House; 2012. Doc12rg12

doi: 10.3205/12rg12, urn:nbn:de:0183-12rg126

This is the translated version of the article.
The original version can be found at: http://www.egms.de/de/meetings/rg2012/12rg12.shtml

Published: May 30, 2012

© 2012 Lipski et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

Background: Cat scratch disease is transmitted via cat scratches as well as flea of cats and dogs. Infection rates for cats in europe range from 12 to 90%. The clinical relevance is is supposed to be underestimated.

Method: Description of the clinical ophthalmologic presentation of cat scratch disease in selected cases.

Results: Especially macular lipid exudation as well as focal chorioretinal infiltrates should lead to serologic clarification of the presumed diagnosis. In some cases of suspected toxoplasmotic chorioretinitis clinical recovery was achieved only after macrolid antibiotic but not after anti-toxoplasmotic antibiotic therapy.

Conclusions: In cases of neuroretinitis and/or chorioretinitis, bartonella infections should be considered and clarified using simple serologic IFA-tests. Therapy consist of systemic macolide therapy, e.g. azithromycin which in most cases improve recovery.